A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence. Issue 1 (2nd January 2019)

• Record Type: Journal Article
• Authors: Serrita, Jane; Ralevski, Elizabeth; Yoon, Gihyun; Petrakis, Ismene
• Is Part Of: Journal of dual diagnosis. Volume 15:Issue 1(2019)
• Page Start: 46
• Page End: 55
• Publication Date: 2019-01-02
• Subjects: Alcohol -- schizophrenia -- glycine -- treatment; Dual diagnosis -- Periodicals; Mental illness -- Treatment -- Periodicals; Substance abuse -- Treatment -- Periodicals; Diagnosis, Dual (Psychiatry) -- Periodicals; Substance-Related Disorders -- Periodicals; Mental Disorders -- Periodicals; 362.29
• DOI: 10.1080/15504263.2018.1549764
• Languages: English
• ISSNs: 1550-4263

Abstract

Abstract: Objectives: The hypofunctioning of N-methyl-D-aspartate (NMDA) receptors are thought to play an important role in the pathophysiology of schizophrenia. The augmentation of the glutamatergic system through the NMDA receptor may attenuate alcohol craving and use. This study was designed to evaluate the efficacy of glycine, an agonist of the glycine B co-agonist site of the NMDA receptor on alcohol consumption and cravings as well as on negative symptoms in schizophrenia.Methods: Participants ( N = 20) were given 0.8 g/kg glycine or matching placebo (provided in bottles with mixed in solution) each week for the duration of the 12-week trial. Primary outcome measures included drinking, craving for alcohol, and symptoms of schizophrenia. Cognitive functioning (attention, concentration, and memory) was also evaluated.Results: Glycine showed no benefit over placebo in the reduction of heavy drinking days or craving for alcohol over a 12-week treatment period. Nor was there an effect on negative symptoms of schizophrenia or on cognitive functioning.Conclusions: Although our study showed no beneficial effect of glycine over placebo, our results are consistent with the largest trial of glycine treatment in schizophrenia. Diagnosed schizophrenia and alcohol dependence might be more difficult to treat because of more severe psychopathology. This is the first study to date to examine an innovative treatment approach with an amino acid, glycine, as potentially acting on both alcohol intake and negative symptoms of schizophrenia.